Osteoporosis Treatment: When to Discontinue and When to Re-start - Wikidata - thesis-toulmin - TriplyDB

Osteoporosis Treatment: When to Discontinue and When to Re-start

Osteoporosis Treatment: When to Discontinue and When to Re-start

http://www.wikidata.org/entity/Q26858980

about

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.The use of bisphosphonates in women: when to use and when to stop.Safety issues and adverse reactions with osteoporosis management.Multiple Vertebral Osteonecroses (Kümmell's Disease) After 10 Years on Denosumab: Is Osteocyte Apoptosis to Blame?

P2860

Q37298020-45B453EE-0FBD-456B-8C99-900AFC551A4B Q38584336-A47661E5-EE61-4F98-9CD5-D8467427DCD6 Q38677822-8D887F22-E3BF-46D6-BA06-847E9BE43841 Q48365103-0DBF246B-889B-4AB6-8908-4BD80051A8D7

P2860

Osteoporosis Treatment: When to Discontinue and When to Re-start

http://www.wikidata.org/entity/Q26858980

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Osteoporosis Treatment: When to Discontinue and When to Re-start

@ast

Osteoporosis Treatment: When to Discontinue and When to Re-start

@en

Osteoporosis Treatment: When to Discontinue and When to Re-start

@nl

type

label

Osteoporosis Treatment: When to Discontinue and When to Re-start

@ast

Osteoporosis Treatment: When to Discontinue and When to Re-start

@en

Osteoporosis Treatment: When to Discontinue and When to Re-start

@nl

prefLabel

Osteoporosis Treatment: When to Discontinue and When to Re-start

@ast

Osteoporosis Treatment: When to Discontinue and When to Re-start

@en

Osteoporosis Treatment: When to Discontinue and When to Re-start

@nl

P1433

Q26858980-6040E0D6-2B5F-492D-A09F-22B31063E80E

P1476

Q26858980-4714D7D4-7AA9-4A4D-8969-CF6B8BBD6BA5

P2093

Q26858980-197E2469-0901-4AE0-BAF1-99D19C470F50

Q26858980-AD5D5F49-0C7B-44D6-AE72-4FA4C3C93889

Q26858980-F16C9F4C-2CE9-4876-9563-0BD4EDF36352

Q26858980-FE0D93F6-B983-4923-B786-C0EB2E4D7898

P2860

Q26858980-09D23E07-7038-4F99-BE4A-AEC3B6A0DF87

Q26858980-0CCA89F1-8D04-499F-AB59-8C97B74F2F01

Q26858980-34EE6FDF-20F8-4AB3-B045-812613F0EAFD

Q26858980-4F4A358F-B75A-46B8-96B4-FC0D51503D60

Q26858980-529A3A8A-4EBD-4F15-8704-C491643326D0

Q26858980-53DA7AA9-ED85-4309-BA5D-D6C30BFFE3F4

Q26858980-56EA245D-C416-41EE-BDB3-DA4F16CCC981

Q26858980-5DFF42C2-ABBA-4763-90A1-D8D99A7680F6

Q26858980-61F625D3-AD2E-4087-9443-0838CDC78F92

Q26858980-629BA990-EB6E-4D64-B969-228E5B8528D0

P2888

Q26858980-399D7942-FD3C-4696-897D-6A247F98ADC1

P304

Q26858980-9CFEE30F-CB6A-4D76-90D6-2546AEBFA456

P31

Q26858980-813FED27-1418-499D-B0B3-277B196FBB57

P3181

Q26858980-EFDA37C2-86B7-4D4C-A209-D55EC1652064

P356

Q26858980-BE3D085D-FD58-40F6-9B8E-E7EFCE065A57

P407

Q26858980-9929F9B1-F9C7-4128-9CB8-AEC1A4F4BB41

P433

Q26858980-7C1E360C-4F0B-45D5-B4A5-F10F0663F01E

P478

Q26858980-71A9161E-71EA-49E0-8107-FA0A93E9ADBA

P50

Q26858980-8A9A562F-BBAF-4622-9122-84FC71906A59

P577

Q26858980-715D45FA-D289-4912-AFCE-0DC8681816AA

P6179

Q26858980-5B2FC3A7-C7AD-4E16-BD52-0893033D7C8E

P698

Q26858980-3CD992D6-E8B7-4DA4-85C8-C97F428ED1D4

P921

Q26858980-123632E8-D24D-4EB4-85B5-E68F4E0554C4

P932

Q26858980-8ADC8369-462E-4AF5-80FF-5334B786AA4F

P3181

P356

P1433

P1476

Osteoporosis Treatment: When to Discontinue and When to Re-start

@en

P2093

Davide Gatti

http://www.w3.org/2001/XMLSchema#string

Elena Fracassi

http://www.w3.org/2001/XMLSchema#string

Maurizio Rossini

http://www.w3.org/2001/XMLSchema#string

Silvano Adami

http://www.w3.org/2001/XMLSchema#string

P2860

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.

Bisphosphonates for osteoporosis--where do we go from here?

P2888

P304

323-335

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4842067

http://www.w3.org/2001/XMLSchema#string

P356

10.4248/BR201304003

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1002402987

http://www.w3.org/2001/XMLSchema#string

P698

26273510

http://www.w3.org/2001/XMLSchema#string

P921

P932

4472120

http://www.w3.org/2001/XMLSchema#string